Withdrawal of non-binding proposal

26^th Aug 2015

In the Company’s announcement of the conclusion of its strategic review released on 18 August, 2015, reference was made to a non-binding preliminary proposal of US$110 million for the Company’s Point-of-Care business. That proposal has now been withdrawn.

The proposals referenced in the Company’s announcements released on 24 August, 2015 are not affected.

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF Diagnostics to showcase at Medica 2021 STAT-Site® WB β-ketone and glucose handheld analyzer live & in person

EKF Diagnostics will be exhibiting live & in person at Medica (Hall 3 Stand B71) for the first time in mainland Europe in two years.

Medica 2021

Medica is the world’s largest medical trade fair. For more than 40 years it has been firmly established on every professional's calendar attracting over 40,000 delegates and over 5,000 exhibitors from 70 countries in 17 halls.

Luke Daum - inventor of PrimeStore® MTM - joins EKF Diagnostics as Chief Scientific Officer

Eminent infectious disease diagnostics expert to further boost EKF’s Life Science and Molecular Diagnostics offering

EKF Diagnostics to showcase new handheld β-ketone and glucose analyzer at AACC 2021

First live viewing of EKF’s STAT-Site^® WB analyzer for reliable and efficient dual analyte measurement from whole blood in seconds

49 trees to be planted as part of EKF & Yolk Recruitment partnership